Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Routine +

Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging

FDA Clearance Confirms Timeline, But Cash Burn Threatens Commercial Launch Viability

By The Northwire Desk — AI Analysis Apr 20, 2026 · 07:00 CNVI · 0.425 Conavi Medical Corp.
Executive Summary
  • On April 20, 2026, Conavi Medical announced it received U.S. FDA 510(k) clearance for its next-generation hybrid IVUS-OCT imaging system (Novasight Hybrid).
  • The clearance enables the company to initiate a commercial launch in the United States, targeted for the second half of 2026.
  • The system integrates intravascular ultrasound and optical coherence tomography into a single workflow, allowing simultaneous visualization of vessel structures.
  • This announcement follows a $12 million equity offering closed on January 13, 2026, which was explicitly earmarked for FDA clearance efforts and U.S. market launch preparations.
  • Previous guidance provided in February 2026 anticipated this clearance within the first half of 2026; the April announcement confirms adherence to that timeline.
Material Impact
  • Expectation vs. Reality: The news is consistent with previous guidance issued on February 26, 2026, which stated an anticipated clearance in H1 2026. As such, this does not represent a surprise upside event but rather the execution of a previously communicated roadmap.
  • Commercial Viability: While regulatory risk is removed for the U.S. market, the company faces significant commercialization risks. The cash runway is tight relative to the capital required for a full-scale launch (sales force, marketing, inventory).
  • Price Impact: The stock price ($0.43) remains below the January 2026 offering price of $0.45. Investors who participated in the recent financing are currently underwater, which may limit upside momentum until the share price reclaims the $0.45 level.
  • Risk Profile: The clearance is a necessary step for revenue generation but does not guarantee commercial success or immediate profitability given the high operating burn rate observed in Q1 FY26 ($5.1 million operating loss).
CNVI · Price
Company Overview
  • Company Profile: Conavi Medical Corp. is a medical device company focused on intravascular imaging technologies for coronary interventions.
  • Flagship Project: The Novasight Hybrid™ system, which combines IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography).
  • Development Status: Next-generation system received FDA 510(k) clearance in April 2026. First-generation system is already cleared in U.S., Canada, China, and Japan.
  • Market Opportunity: Targeting the coronary intravascular imaging market estimated at over $4 billion annually.
Read the original news release →

More from Conavi Medical Corp.

Jun 29, 2026 · 07:00

Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund

Financings May 28, 2026 · 08:00

FDA Clearance Delivered But Dilution and Cash Burn Threaten Near-Term Stability

Earnings May 11, 2026 · 07:00

Conavi Medical files for fresh equity offering as cash reserves dwindle ahead of U.S. Novasight launch, raising dilution fears amid a share price plumbing near all-time lows.

Financings Apr 23, 2026 · 07:00

Conavi Medical Awarded 2026 TAG Innovation

Regulatory Feb 26, 2026 · 07:05

Conavi Medical Reports Fiscal First Quarter 2026 Results and Operational Highlights

Financings Feb 13, 2026 · 12:29

Conavi highlights hybrid IVUS-OCT study results

Production / Operations